No.

Experimental reported Activity, (Pa)*

Predicted theoretical biological activity, (Pa)*

Related reference

1

Inhibitor of the glycolytic enzyme enolase 2

Stroke treatment (0.761); Neuroprotector (0.744); Acute neurologic disorders treatment (0.663); Antineoplastic (sarcoma) (0.646); Antinephrotoxic (0.587); Antiseborrheic (0.578)

(15, 16, 21)

2

Not reported

Stroke treatment (0.979); Antiviral (0.897); Antiviral (HIV) (0.887)

Antinephrotoxic (0.701); Bone formation stimulant (0.653)

(29, 31)

3

Not reported

Antibiotic Glycopeptide-like (0.984); Stroke treatment (0.538) Antischistosomal (0.510)

(21)

4

Not reported

Antiarthritic (0.963); Anti-inflammatory (0.942); Acute neurologic disorders treatment (0.765); Bone formation stimulant (0.615) Antinephrotoxic (0.608); Stroke treatment (0.567)

Leukopoiesis stimulant (0.542); Bone diseases treatment (0.539)

(30)

5

Not reported

Bone formation stimulant (0.813); Bone diseases treatment (0.803) Acute neurologic disorders treatment (0.650); Antinephrotoxic (0.604) Antiosteoporotic (0.560); Leukopoiesis stimulant (0.526)

(31)

6

Not reported

Acute neurologic disorders treatment (0.834); Stroke treatment (0.583) Bone formation stimulant (0.574); Bone diseases treatment (0.536) Anesthetic general (0.517); Leukopoiesis stimulant (0.506)

(31)

7

Not reported

Acetylesterase inhibitor (0.618); Anticonvulsant (0.533)

(19, 20)

8

Not reported

Anticonvulsant (0.664); Acetylesterase inhibitor (0.637); Acute neurologic disorders treatment (0.513)

(19, 20)

9

Not reported

Acetylesterase inhibitor (0.687); Myasthenia Gravis treatment (0.562)

(19, 20)

10

Not reported

Cognition disorders treatment (0.765)

(19, 20)

11

Not reported

Calcium regulator (0.548); Antihypertensive (0.503)

(32)

12

Not reported

Acute neurologic disorders treatment (0.852); Stroke treatment (0.582) Bone diseases treatment (0.580); Bone formation stimulant (0.531)

(33)

17a

Not reported

Acetylesterase inhibitor (0.611); Insulinotropin antagonist (0.568)

Present study

17b

Not reported

Spasmolytic, urinary (0.954)

Present study

17c

Not reported

Acetylesterase inhibitor (0.572); Immunostimulant (0.522)

Present study

17d

Not reported

Acetylesterase inhibitor (0.618); Immunostimulant (0.544)

Present study

17e

Not reported

Acetylesterase inhibitor (0.618); Immunostimulant (0.544)

Present study

17f

Not reported

Purinergic P2Y2 antagonist (0.512)

Present study

17g

Not reported

No activities with Pa > 0.5

Present study

17h

Not reported

General pump inhibitor (0.600)

Present study